Exelixis Q3 Revenue $658.7M, EPS $0.85; Tax Guidance Cut, Azurity Deal Signed
EXEL sits 84% above its 52-week low of $36.
Summary
Exelixis posted Q3 revenue of $658.7 million and diluted EPS of $0.85, held its full-year revenue range but cut its tax-rate guidance, and disclosed an Azurity settlement delaying that generic's U.S. entry to December 2030.
Key Events · Earnings and Guidance · EXEL
-
Q3 Revenue Up 10% to $658.7M
Total revenues were $658.7 million versus $597.8 million a year earlier, with net product revenues of $604.9 million versus $542.9 million. GAAP diluted EPS was $0.85 and non-GAAP diluted EPS was $0.94.
-
Tax Guidance Cut Lifts Earnings
FY2026 total revenue guidance was held at $2.500-$2.550 billion, but the effective tax rate guide dropped to 16%-18% from 21%-23%, a direct boost to net income with no change to the top line.
-
Azurity Settlement Sets 2030 Entry
The October 28, 2026 settlement and license agreement lets Azurity market its proposed 505(b)(2) NDA product in the U.S. beginning December 1, 2030, if approved; the generic cabozantinib effective date stays January 1, 2031.
-
STELLAR-304 Topline Slips to Q1 2027
Exelixis now expects topline results from the phase 3 STELLAR-304 nccRCC trial in the first quarter of 2027. The zanzalintinib CRC PDUFA date remains March 3, 2027 after the FDA's three-month extension.
Analysis · EXEL · Life Sciences
Revenue grew 10% year over year to $658.7 million and GAAP diluted EPS rose to $0.85 from $0.69, so the commercial franchise is still compounding even as the zanzalintinib launch slips. The quietly important line is the effective tax rate guide cut to 16%-18% from 21%-23%, which lifts full-year earnings without any change to the revenue range. Two legal items also landed: the Azurity settlement pushes that 505(b)(2) entrant's U.S. entry to December 1, 2030, and the Federal Circuit's August ruling keeps MSN's generic cabozantinib off the market until at least January 15, 2030. Against that, STELLAR-304 topline has moved to Q1 2027 and the zanzalintinib CRC PDUFA date sits at March 3, 2027 after the FDA's three-month extension.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EXEL was trading at $66.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.4B. The 52-week trading range was $36.00 to $67.52. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.